Clinical Evaluation of Idi Vallathy Mezhugu (IVM) for the Management of Vali Azhal Keel Vayu (Rheumatoid Arthritis)â?? A Pilot study

ational Institute of Siddha0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年4月4日

试验速览

暂无简介。

•Both sexes of age between 16 to 60.
•Patient who meets the standard, European League against Rheumatism EULAR 2010 classification criteria.
•A score >= 6 points is required for classification as definite RA.
•Patients who are willing to attend OPD and IPD
•Patients who are willing to undergo laboratory investigation.
•Patient who are willing to sign the informed consent stating that he/ she will consciously stick to the treatment during 48 days but can stop out of the trail of his /her own conscious discretion.
•Patients who are willing to follow diet restriction

•Known C/O Other Auto immune diseases.
•Patients receiving immunosuppressant, corticosteroids, antipsychotics, other arthritis medications including painkillers.
•Known C/O Systemic Hypertension (SHT)
•Known C/O Diabetes
•Pregnant women.
•Lactating women.
•History of trauma
•Known C/O Any other arthritis
•Systemic complication of rheumatoid arthritis Patient.
•Characteristic deformities of hand and feet in Rheumatoid Arthritis
•Known C/O any other serious systemic illness like Cancer, Cardiac disease, Renal disease, Liver disorders, Neurological disorders.
•Patients who had already participated in a new drug study in the past 3 months.

发起方